Evidence map›Paper›PMID 32486455›Full record

ArticleMolecules (Basel, Switzerland)2020

Bioassay Guided Isolation and Docking Studies of a Potential β-Lactamase Inhibitor from

Mahmoud A Elfaky, Ali M El-Halawany, Abdulrahman E Koshak, Khalid Z Alshali, Moustafa E El-Araby, Maan T Khayat, Hossam M Abdallah

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Computational Evaluation ofCurrent computer-aided drug design · 2026
    Article
  2. Review
  3. Review
  4. Isolation of quinic acid from droppedFrontiers in chemistry · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Repurposing of antidiabetics as Serratia marcescens virulence inhibitors.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mahmoud A ElfakyDepartment of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-3931-9353
Ali M El-HalawanyDepartment of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.ORCID 0000-0002-5864-1674
Abdulrahman E KoshakDepartment of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-0179-9793
Khalid Z AlshaliDepartment of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Moustafa E El-ArabyDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-7932-2226
Maan T KhayatDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Hossam M AbdallahDepartment of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-0234-7492

Funding

Deanship of Scientific Research (DSR), King Abdulaziz University RG/14/166/40
6 · The paper itself

Abstract

Infectious diseases are the second major cause of death worldwide, and the ability to resist multiple classes of antibiotics is the key factor in enabling pathogenic organisms to survive and spread in the nosocomial environment. Unfortunately, the available β-lactamase inhibitors are not efficient against β-lactamase B, C, and D which necessitates discovering either broad spectrum β-lactamase inhibitors or new β-lactam antibiotics resistant to bacterial enzymes. In this regard, products of natural origin have prompted the disclosure of new compounds and medicinal leads. Chloroform fraction of

Indexed as

Anti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasesBinding SitesBiological AssayCephalosporinsChloroformEscherichia coliFuransKlebsiella pneumoniaeMagnetic Resonance SpectroscopyMagnoliopsidaMicrobial Sensitivity TestsModels, MolecularMolecular Docking SimulationProtein BindingAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasesCephalosporinsChloroformFuransantimicrobial resistancebio-guided fractionationClutia myricoidesKlebsiella pneumoniaemolecular dockingβ-lactamase

Identifiers

PMID32486455
PMCPMC7321312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.